This document discusses cross-border mergers and acquisitions (M&As) in the pharmaceutical industry and lessons that can be applied to Vietnamese pharmaceutical companies. It covers M&A motives, types of M&As, the M&A process, and factors to consider from the OLI model like ownership advantages and location advantages. It analyzes characteristics of the pharmaceutical industry like high R&D costs, patent protection, and industry concentration. It implies that Vietnamese drug companies could benefit from cross-border M&As to gain access to capital and R&D resources, and that the pharmaceutical industry's dynamics make consolidation through M&A appealing.

1. How to utilize cross-border M&A to increase the operational efficiency of Vietnamese pharmaceutical companies Lessons learnt from M&A worldwide S3095371_ VU LIEN HUONG

2. Research methodology M&A M&A motives Synergies, Tax, Defense, Geography… M&A type Horizontal, vertical… M&A approach manner Hostile vs. Friendly M&A process Pre-merger Post-merger FDI FDI types Green field, M&A, Joint venture OLI Model Ownership Location Internationalization Cross border M&A Pharmaceutical industry

4. FDI Definition Advantages Disadvantages Greenfield Build one new plant F  F1 Best control Start with clean site Most time and effort consuming  opportunities lost Cross border M&A Acquire or merge with existed firm F + L = F Shorten introducing time Utilize local knowledge and existed facilities No absolute control Time to synchronize two systems Joint venture Corporate with local firm to build a new one F + L = L Risk sharing Potential synergies Risk of conflicts Lack of full control Lack of trust Creating future competitors

6. M&A

7. Motives Motives  type, manners Some… add value Some… do not Some… even destroy.

8. Process

12. HEALTHY INDUSTRY HEALTHY SOCIETY Thanks for listening